Formononetin Regulates Multiple Oncogenic Signaling Cascades and Enhances Sensitivity to Bortezomib in a Multiple...

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Multiple myeloma (MM) is a hematological malignancy characterized by uncontrolled plasma cell proliferation.
• Current MM therapies, including proteasome inhibitors like bortezomib, face challenges with drug resistance and disease progression.
• Identifying novel therapeutic agents and strategies to overcome resistance is crucial for improving MM patient outcomes.

Purpose of the Study:

• To investigate the anti-neoplastic effects of formononetin (FT) in multiple myeloma (MM).
• To elucidate the molecular mechanisms underlying FT's action against MM cells.
• To evaluate the synergistic potential of FT in combination with bortezomib (Bor) for MM therapy.

Main Methods:

• In vitro studies using MM cell lines to assess apoptosis and proliferation.
• Analysis of signaling pathways including nuclear factor-κB (NF-κB), phosphatidylinositol 3-kinase (PI3K)/AKT, and activator protein-1 (AP-1) activation.
• In vivo studies using a preclinical MM mouse model to evaluate tumor growth inhibition.

Main Results:

• Formononetin (FT) significantly enhanced bortezomib (Bor)-induced apoptosis and reduced proliferation in MM cells.
• FT treatment led to decreased levels of key tumorigenic proteins essential for MM progression and survival.
• FT effectively inhibited persistent activation of NF-κB, PI3K/AKT, and AP-1 signaling pathways in MM cells.
• FT augmented the tumor growth-inhibitory effects of Bor in a preclinical MM mouse model.

Conclusions:

• Formononetin (FT) exhibits potent anti-neoplastic activity against multiple myeloma (MM) by modulating critical oncogenic signaling pathways.
• FT enhances the efficacy of proteasome inhibitors like bortezomib (Bor), suggesting a promising combination therapy for MM.
• FT's ability to regulate transcription factors involved in myeloma growth presents a novel therapeutic avenue for MM treatment.